Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gout Flares & the NLRP3 Inflammasome

Katie Robinson  |  Issue: June 2025  |  May 30, 2025

Inflammasome activation occurs by a two-step process, and typically, two distinct signals are needed to initiate each of these steps. In gout, “MSU crystals trigger step two in this process, but often a second factor is required to initiate step one,” Dr. Poulson explains. Factors known to trigger step one include alcohol, infection and saturated fatty acids, “all of which are also implicated as gout flare triggers.”

“The need for two signals to activate the NLRP3 inflammasome may explain why gout flares only occur sporadically in joints despite the continual presence of MSU crystals and why factors such as alcohol consumption can trigger NLRP3 inflammasome activation and gout flares in individuals with MSU crystal deposits, but not in individuals without,” Dr. Poulson says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Gout flares will self-resolve, even in the absence of treatment, Dr. Poulson explains. Many of the mechanisms involved in initiating the inflammatory cascade in the gout flare also trigger pathways to turn it off, ensuring that inflammation can only persist for a finite period.

“For instance, NLRP3 inflammasome activation results in self-cleavage of the enzyme caspase 1. This activates caspase 1, allowing it to then activate IL-1β, a key step in initiating the inflammatory cascade in the gout flare. However, self-cleavage also targets caspase 1 for destruction, ensuring that caspase 1 activity is self-limiting,” Dr. Poulson says.

Click to enlarge.

Neutrophil activation and the resultant increased production of inflammatory cytokines plays “a central role in amplifying the inflammatory response in the gout flare and is associated with the increased intensity of symptoms during initial gout flare development. However, neutrophils are also critical for flare resolution,” Dr. Poulson explains. Aggregated neutrophil elastase traps (NETs) are “released by neutrophils sequester chemokines and inflammatory cytokines. As NETs accumulate, they also form a coating on MSU crystals, reducing the inflammasome-activating ability of the crystals. Neutrophils undergoing apoptosis at the end of their life cycle are a major source of anti-inflammatory mediators, such as TGF-β [transforming growth factor beta], which is key for driving a switch in macrophage polarization from M1 to M2.”

Case Study

In the clinical case, a 60-year-old man presented with a six-hour history of pain and swelling in his right, first metatarsophalangeal (MTP) joint. He described a throbbing sensation in his big toe joint that woke him overnight. Over one hour, he developed intense pain—described as the worst he had ever experienced, with 9/10 in severity—redness, heat and swelling in the joint. The patient could not move the joint, put weight on his foot or wear a shoe.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline ArthritisResearch ReviewsResearch Rheum Tagged with:Arthritis & Rheumatologycase reportGoutGout Resource CenterImmunology InsightsNACHT-LRR-PYD-containing protein 3NLRP3

Related Articles

    The Expanded Role of the Inflammasome in Human Disease

    August 1, 2010

    Exploring advances, evaluating what remains to be done

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Clinical Applications of Dual-Energy Computed Tomography for Rheumatology

    June 1, 2014

    Advanced imaging technique allows physicians to detect deposition of monosodium urate crystals not apparent in physical exams and better diagnose gout

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences